Sponsor
Poznan University of Medical Sciences
Clinical research sponsor
How to interpret these research links
Connected source recordsThe exact organization name Poznan University of Medical Sciences appears in 36 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
36 shownTDM-Guided Treatment With SSRIs in Hospitalized Adults and ChildrenNCT07478796 · lead sponsor · 2025-04-03
RECRUITINGTelemedical Algorithm-Supported Care for HypertensionNCT06722625 · lead sponsor · 2023-10-01
RECRUITINGInsulin Therapy and Lipoproteins' Profile in Type 1 Diabetes.NCT02306005 · lead sponsor · 2014-11-01
RECRUITINGType 2 Diabetes and Pregnancy a Single-arm Interventional StudyNCT07602036 · lead sponsor · 2026-05-01
NOT_YET_RECRUITINGMarathon Runners With Type 1 DiabetesNCT06935903 · lead sponsor · 2023-08-30
COMPLETEDEffect of Flozin (dapagliflozin) Administration on Myocardial and Peripheral Vascular RemodelingNCT06679179 · lead sponsor · 2023-03-10
UNKNOWNHypoglycemia Awareness Study in Diabetes Type 1NCT05620927 · lead sponsor · 2022-11-24
UNKNOWNAssessment of the Effect of Probiotic Supplementation on Proinflammatory Mechanisms Induced by Systemic Treatment in Women With Breast CancerNCT07607548 · lead sponsor · 2022-10-18
COMPLETEDEffect of Probiotics or Berberine in Hepatic Steatosis Markers, Cardiometabolic and Microbiotic Profile in NAFL.NCT05523024 · lead sponsor · 2022-08-02
UNKNOWNThe Effect of Glucose Level and Diabetes Mellitus on Ctrough of OlaparibNCT05081765 · lead sponsor · 2021-09-20
UNKNOWNAssessment of Progranulin and FAM19A5 Protein Blood Levels in Metabolic SyndromeNCT04451616 · lead sponsor · 2020-07-03
UNKNOWNDiabetes Type 1 and Fitness.NCT04968171 · lead sponsor · 2020-01-01
UNKNOWNFemale Obesity Cohort and Intervention Study Group (MOCART Study Group)NCT04924738 · lead sponsor · 2017-12-03
UNKNOWNEffect of Dietary Modifacation on Microbiota in Overweight and Obese Polycystic Ovary Syndrome PatientsNCT03325023 · lead sponsor · 2017-05-20
UNKNOWNEffect of Oral Supplementation With ProbioticsNCT03100162 · lead sponsor · 2016-02-27
COMPLETEDAnthropometric Parameters, Metabolic Profile and Function of the Respiratory System in Obese PatientsNCT03346421 · lead sponsor · 2016-02-01
UNKNOWNReduction of Left Ventricular Hypertrophy After Eplerenone TherapyNCT03186742 · lead sponsor · 2014-07-01
COMPLETEDSpirulina Supplementation and Cardiovascular Risk in Obese Caucasians With Treated HypertensionNCT02575690 · lead sponsor · 2013-01-01
COMPLETEDEndurance-strength Training in Obese WomenNCT04793451 · lead sponsor · 2012-12-06
COMPLETEDEffect of Endurance and Endurance-Strength Training on Inflammatory Markers in Women With Abdominal ObesityNCT03444207 · lead sponsor · 2012-12-06
COMPLETEDThe Influence of Partial Remission Phase of Type 1 Diabetes on Patient OutcomeNCT02220257 · lead sponsor · 2012-01-01
UNKNOWNSalusin-alpha - a New Factor in the Pathogenesis of Lipid Abnormalities in Hemodialysis PatientsNCT01448174 · lead sponsor · 2011-10-01
COMPLETEDMetformin Therapy in Type 1 Diabetes Mellitus.NCT01889706 · lead sponsor · 2009-01-01
UNKNOWNSupplementation With Sirtuin Activators in Women With Increased Body WeightNCT07245979 · collaborator · 2025-10-08
RECRUITINGComparison of 40% Glucose Solution and Autologous Blood Patch Pleurodesis for Postoperative Air Leak After Lung ResectionsNCT06936969 · collaborator · 2023-12-22
RECRUITINGChAracterization of Patients and Treatment OUtcomes in Severe Tricuspid RegurgitationNCT06838611 · collaborator · 2023-11-14
RECRUITINGCladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).NCT05961644 · collaborator · 2022-10-03
RECRUITINGCreatine Supplementation and Resistance Training in Patients With Breast CancerNCT05878106 · collaborator · 2024-04-08
UNKNOWNEmpagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart FailureNCT05776043 · collaborator · 2022-03-15
UNKNOWNLevosimendan In Ambulatory Heart Failure PatientsNCT04705337 · collaborator · 2021-12-15
TERMINATEDPrecision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)NCT05537558 · collaborator · 2021-09-09
UNKNOWNOptimal Growth of Preterm Infants With Growth RestrictionNCT02999945 · collaborator · 2019-03-01
WITHDRAWNInfluence of Plantago Major on Mineral Metabolism and Selected Biochemical Parameters in Obese WomenNCT03439540 · collaborator · 2018-03-01
COMPLETEDThe Influence of Hypotensive Drugs on Mineral Status in Experimental and Clinical StudiesNCT03465462 · collaborator · 2016-01-02
COMPLETEDEffects of an Indoor Cycling Program on Cardio-Metabolic Factors in Women With Obesity and Normal Body WeightNCT04456192 · collaborator · 2013-01-01
COMPLETEDIntra-Operative Electron Boost and Hypofractionated Whole-Breast Irradiation During Breast-conserving Treatment (BCT)NCT01343459 · collaborator · 2011-01-01
COMPLETEDDrugs studied in this sponsor's trials
7 mapped RxNorm conceptsThese drug records are connected through ClinicalTrials.gov studies listing Poznan University of Medical Sciences as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.
atorvastatin1
dapagliflozin 10 MG1
empagliflozin 10 MG1
escitalopram1
fluoxetine1
levosimendan1
placebo1
atorvastatin RxCUI 83367 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
dapagliflozin 10 MG RxCUI 1488565 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting
1 trial
empagliflozin 10 MG RxCUI 1545654 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting
1 trial
escitalopram RxCUI 321988 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting
1 trial
fluoxetine RxCUI 4493 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting
1 trial
levosimendan RxCUI 73107 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting
1 trial
placebo RxCUI 8375 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting
1 trial
Sponsor roles
lead sponsor23
collaborator13
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.